Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tunable cell therapies

Sigilon's allogeneic cell therapy implants offer long-term but flexible dosing

Sigilon Therapeutics Inc. is developing allogeneic cell therapy implants for protein deficiency disorders that thread the needle between protein replacement therapies that require frequent dosing, and gene and cell therapies that are hard to dose-adjust.

The biotech’s Afibromer technology encapsulates cells that are engineered to express therapeutic proteins over a sustained period within biocompatible spheres, or beads, which consist of chemically modified alginate.

The beads shield the cells from immune attack, so patients would

Read the full 747 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers